Loading stock data…
BridgeBio Pharma, Inc. (BBIO)
$74.76-0.08 (-0.11%)
Market ClosedLast close Sep 8
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BridgeBio Pharma, Inc. in the Healthcare sector is trading at $74.76 with a market capitalization of $12.8B. Wall Street consensus targets $109.10 (21 analysts), implying a +45.9% move over the next 12 months. The stock is currently 20% below its 52-week high of $93.42, remaining 1.2% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 10 is oversold, raising the odds of a near-term bounce. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +45.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 10) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $194.51M↑ | $154.18M↑ | $120.70M↑ | $110.56M↓ | $116.63M |
| Gross Profit | $184.58M↑ | $146.07M↑ | $114.14M↑ | $106.91M↓ | $113.99M |
| Operating Income | -$105.96M↑ | -$128.43M↑ | -$136.36M↓ | -$133.47M↓ | -$103.80M |
| Net Income | -$164.04M↑ | -$192.86M↓ | -$182.74M↓ | -$181.90M↓ | -$167.42M |
Peer Comparison
JNJUNHPFE
Fundamentals
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of c...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.82B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.02
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
31.67%
Volume
Today's trading volume
2.08M
Recent News
BridgeBio (BBIO) Reported Signs of Cardiac Reversal With Acoramidis. How Much Weight Should Investors Give a Completer Analysis?
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is asking investors to look beyond disease stabilization in transthyretin amyloid cardiomyopathy, or ATTR-CM. New cardiac magnetic resonance imaging data from the Phase 3 ATTRibute-CM study and its open-label extension suggested that some acoramidis-treated patients experienced improvements in cardiac structure and function. A separate post-hoc analysis found that treatment preserved more […]
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, reshaping the economics of competition.
Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President
President Donald Trump has secured new drug pricing agreements with nine pharmaceutical companies, with an aim to align the prices of drugs in the U.S. with international prices. The companies include Alcon Inc., Astellas Pharma, BeOne Medicines Ltd., BridgeBio, CSL,...
What Does BridgeBio Pharma (BBIO) Gain From Its New US Drug Access Deal?
BridgeBio Pharma (NasdaqGS:BBIO) has entered a voluntary agreement with the U.S. government to expand access to its medicines and lower drug costs for American patients. The arrangement widens Medicaid access through a unique pricing and reimbursement model tailored to public health programs. The agreement keeps current Medicare Part D offerings in place without new pricing mandates on those products. Orphan indication drugs are excluded from future pricing commitments under this framework,...
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.